New iron formula may offer better anemia relief after gastric sleeve surgery
NCT ID NCT07366502
First seen Jun 27, 2026 · Last updated Jul 14, 2026 · Updated 2 times
Summary
This study tests whether a low-dose liposomal iron supplement works better and causes fewer stomach issues than the standard high-dose iron pills for people with iron deficiency anemia after sleeve gastrectomy. About 70 adults who had this weight-loss surgery at least 6 months ago will take either the new liposomal iron or conventional iron for 24 weeks. Researchers will measure changes in hemoglobin and iron levels to see which approach is more effective and easier to tolerate.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 70 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Sep 2025
- Expected to finish
-
Jul 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 65 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria * Age between 18 and 65 years * History of laparoscopic sleeve gastrectomy performed at least 6 months prior to enrollment * Diagnosis of iron deficiency anemia, defined as: * Hemoglobin \<12 g/dL in women or \<13 g/dL in men, and * Serum ferritin \<30 ng/mL or transferrin saturation (TSAT) \<20% * Mild to moderate anemia (hemoglobin ≥9 g/dL) * Ability to take and swallow oral medications * Willingness to participate and provide written informed consent Exclusion Criteria * Active gastrointestinal disease (e.g., inflammatory bowel disease, peptic ulcer disease, or gastrointestinal bleeding) * Chronic kidney disease with estimated GFR \<30 mL/min/1.73 m² * Use of oral or parenteral iron, vitamin B12, or folate supplementation within the previous 3 months * Iron overload or hemochromatosis (serum ferritin \>300 ng/mL) * Known allergy or intolerance to iron preparations * Active malignancy * Pregnancy or breastfeeding * Known hemoglobinopathies (e.g., thalassemia, sickle cell disease) * Blood transfusion within the previous 1 month * Cognitive or psychiatric disorder interfering with study participation or protocol adherence
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Conventional iron replacement are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Goztepe Prof.Dr. Suleyyman Yalçın City Hospital
RECRUITINGIstanbul, kadıköy, 34630, Turkey (Türkiye)